^
    Back
    Association details:
    Biomarker:TMB-L
    Cancer:Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor) +
    spartalizumab (PDR001) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO-SITC 2020
    Title:

    Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).

    Published date:
    02/06/2020
    Excerpt:
    The majority of PFS events occurred in the TMB-low/TI-GEP-low subgroup.
    Trial ID:
    COMBI-i